Novel 1-(2-aminopyrazin-3-yl)methyl-2-thioureas as potent inhibitors of mitogen-activated protein kinase-activated protein kinase 2 (MK-2)

被引：17

作者：

Lin, Songnian ^{[1
]}

Lombardo, Matthew ^{[1
]}

Malkani, Sunita ^{[1
]}

Hale, Jeffrey J. ^{[1
]}

Mills, Sander G. ^{[1
]}

Chapman, Kevin ^{[1
]}

Thompson, James E. ^{[1
]}

Zhang, Wen Xiao ^{[1
]}

Wang, Ruixiu ^{[1
]}

Cubbon, Rose M. ^{[1
]}

O'Neill, Edward A. ^{[1
]}

Luell, Silvi ^{[1
]}

Carballo-Jane, Ester ^{[1
]}

Yang, Lihu ^{[1
]}

机构：

[1] Merck Res Labs, Rahway, NJ 07065 USA

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2009年 / 19卷 / 12期

关键词：

MAPKAP kinase 2; MK-2; TNF alpha; Inflammation; Rheumatoid arthritis; Aminopyrazine; Thiourea; RHEUMATOID-ARTHRITIS;

D O I：

10.1016/j.bmcl.2009.04.088

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Novel 1-(2-aminopyrazin-3-yl)methyl-2-thioureas are described as inhibitors of mitogen-activated protein kinase-activated protein kinase 2 (MK-2). These compounds demonstrate potent in vitro activity against the enzyme with IC50 values as low as 15 nM, and suppress expression of TNF alpha in THP-1 cells and in vivo in an acute inflammation model in mice. The synthesis, structure-activity relationship (SAR), and biological evaluation of these compounds are discussed. (C) 2009 Elsevier Ltd. All rights reserved.

引用

页码：3238 / 3242

页数：5

共 50 条

[41] First-in-class mitogen-activated protein kinase (MAPK) p38a: MAPK-activated protein kinase 2 dual signal modulator with anti-inflammatory and endothelial-stabilizing properties
Tulapurkar, Mohan E.
Shirey, Kari Ann
Lugkey, Katerina
Luo, Wendy
Lal, Ritu
Galan, Adam
Mahmoud, Omar
Mcclean, Nathaniel
Thangaraju, Kiruphagaran
Cericola, Daniel
Lewis, Daniel
Murphy, William A.
Fletcher, Steven
MacKerell Jr, Alexander D.
Vogel, Stefanie N.
Shapiro, Paul
Hasday, Jeffrey D.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2025, 392 (03)
[42] Discovery and Characterization of MAPK-activated Protein Kinase-2 Prevention of Activation Inhibitors
Cumming, John G.
Debreczeni, Judit E.
Edfeldt, Fredrik
Evertsson, Emma
Harrison, Martin
Holdgate, Geoffrey A.
James, Michael J.
Lamont, Scott G.
Oldham, Keith
Sullivan, Jane E.
Wells, Stuart L.
JOURNAL OF MEDICINAL CHEMISTRY, 2015, 58 (01) : 278 - 293
[43] Differential induction of TNF-α and NOS2 by mitogen-activated protein kinase signaling pathways during Mycobacterium bovis infection
Méndez-Samperio, P
Ayala, H
Trejo, A
Ramírez, FA
JOURNAL OF INFECTION, 2004, 48 (01) : 66 - 73
[44] Inhibition of the mitogen activated protein kinase ERK1/2 amplifies ochratoxin A toxicity in the proximal tubule of the kidney
C. Sauvant
H. Holzinger
M. Gekle
Mycotoxin Research, 2003, 19 (2) : 118 - 123
[45] SIRT2 is involved in cisplatin-induced acute kidney injury through regulation of mitogen-activated protein kinase phosphatase-1
Jung, Yu Jin
Park, Woong
Kang, Kyung Pyo
Kim, Won
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2020, 35 (07) : 1145 - 1156
[46] 3D-QSAR and molecular docking analysis of biphenyl amide derivatives as p38α mitogen-activated protein kinase inhibitors
Ambure, Pravin Sundarao
Gangwal, Rahul Prakashchand
Sangamwar, Abhay T.
MOLECULAR DIVERSITY, 2012, 16 (02) : 377 - 388
[47] 2-Cyclopropylimino-3-Methyl-1,3-Thiazoline Hydrochloride Inhibits Microglial Activation by Suppression of Nuclear Factor-Kappa B and Mitogen-Activated Protein Kinase Signaling
Kim, Eun-A
Choi, Jiyoung
Han, A. Reum
Cho, Chang Hun
Choi, Soo Young
Ahn, Jee-Yin
Cho, Sung-Woo
JOURNAL OF NEUROIMMUNE PHARMACOLOGY, 2014, 9 (04) : 461 - 467
[48] Knockdown of augmenter of liver regeneration in HK-2 cells inhibits inflammation response via the mitogen-activated protein kinase signaling pathway
Ruyu Yan
Ling Zhang
Ning Xia
Qi Liu
Hang Sun
Hui Guo
Inflammation Research, 2015, 64 : 453 - 462
[49] Knockdown of augmenter of liver regeneration in HK-2 cells inhibits inflammation response via the mitogen-activated protein kinase signaling pathway
Yan, Ruyu
Zhang, Ling
Xia, Ning
Liu, Qi
Sun, Hang
Guo, Hui
INFLAMMATION RESEARCH, 2015, 64 (06) : 453 - 462
[50] Losmapimod, a novel p38 mitogen-activated protein kinase inhibitor, in non-ST-segment elevation myocardial infarction: a randomised phase 2 trial
Newby, L. Kristin
Marber, Michael S.
Melloni, Chiara
Sarov-Blat, Lea
Aberle, Laura H.
Aylward, Philip E.
Cai, Gengqian
de Winter, Robbert J.
Hamm, Christian W.
Heitner, John F.
Kim, Raymond
Lerman, Amir
Patel, Manesh R.
Tanguay, Jean-Francois
Lepore, John J.
Al-Khalidi, Hussein R.
Sprecher, Dennis L.
Granger, Christopher B.
LANCET, 2014, 384 (9949) : 1187 - 1195

← 1 2 3 4 5 →